Last reviewed · How we verify
NCT03199586
Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
Phase 1 trial testing NP-G2-044 in Breast Cancer in 23 participants. Completed in 7 May 2020.
7 May 2020
Quick facts
| Lead sponsor | Novita Pharmaceuticals, Inc. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 23 |
| Start date | 21 December 2017 |
| Primary completion | 7 May 2020 |
| Estimated completion | 7 May 2020 |
| Sites | 3 locations across United States |
Drugs / interventions tested
- NP-G2-044 — full drug profile →
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Pancreas Cancer — all drugs for Pancreas Cancer →
- Prostate Cancer — all drugs for Prostate Cancer →
- Lung Cancer — all drugs for Lung Cancer →
Sponsor
Novita Pharmaceuticals, Inc. — full company profile →
Who can join
18 and older, any sex, with Breast Cancer or Pancreas Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Phase 1 A: First-in-human phase 1 study to determine safety of NP-G2-044 when given orally on a daily X 28 days followed by a 14 day rest period.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Involvement of Actin and Actin-Binding Proteins in Carcinogenesis.
Izdebska M, Zielińska W, Hałas-Wiśniewska M, Grzanka A. · · 2020 · cited 89× · PMID 33036298 · DOI 10.3390/cells9102245 -
Actin-Associated Proteins and Small Molecules Targeting the Actin Cytoskeleton.
Gao J, Nakamura F. · · 2022 · cited 44× · PMID 35216237 · DOI 10.3390/ijms23042118 -
Clinical and Pre-Clinical Evidence of Carbonic Anhydrase IX in Pancreatic Cancer and Its High Expression in Pre-Cancerous Lesions.
Strapcova S, Takacova M, Csaderova L, Martinelli P, et al · · 2020 · cited 20× · PMID 32707920 · DOI 10.3390/cancers12082005 -
Fascin-1 in Cancer Cell Metastasis: Old Target-New Insights.
Sarantelli E, Mourkakis A, Zacharia LC, Stylianou A, et al · · 2023 · cited 18× · PMID 37511011 · DOI 10.3390/ijms241411253 -
Role of actin cytoskeleton in podocytes.
Sever S. · · 2021 · cited 18× · PMID 33188449 · DOI 10.1007/s00467-020-04812-z -
Cytoskeletal and Cytoskeleton-Associated Proteins: Key Regulators of Cancer Stem Cell Properties.
Li Y, Wang D, Ge H, Güngör C, et al · · 2022 · cited 14× · PMID 36355541 · DOI 10.3390/ph15111369 -
Targeting FSCN1 with an oral small-molecule inhibitor for treating ocular neovascularization.
Bai W, Ren JS, Xia M, Zhao Y, et al · · 2023 · cited 13× · PMID 37596693 · DOI 10.1186/s12967-023-04225-0 -
Fascin-1: Updated biological functions and therapeutic implications in cancer biology.
Li CH, Chan MH, Liang SM, Chang YC, et al · · 2022 · cited 12× · PMID 37082587 · DOI 10.1016/j.bbadva.2022.100052
Verify or expand the search:
- PubMed search for NCT03199586
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of NP-G2-044
Trials testing the same drug.
- NCT07109414 — Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1) · Phase 2, PHASE3 · active not recruiting
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Novita Pharmaceuticals, Inc. trials
Trials by the same sponsor.
- NCT07109414 — Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1) · Phase 2, PHASE3 · active not recruiting
- NCT05023486 — NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies · Phase 1, PHASE2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03199586 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Novita Pharmaceuticals, Inc.
- Last refreshed: 20 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03199586.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing